Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
Research ArticleResearch

Family practice patients’ adherence to statin medications

Nandini Natarajan, R. Wayne Putnam, Alexandra M. Yip and Dawn Frail
Canadian Family Physician December 2007, 53 (12) 2144-2145;
Nandini Natarajan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: nandini.natarajan@dal.ca
R. Wayne Putnam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandra M. Yip
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dawn Frail
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

Large clinical trials have shown that patients with dyslipidemia who take statin medications on a regular basis have substantially fewer major cardiovascular events and lower mortality after 1 to 2 years of continuous treatment.1–6 Despite this evidence, prescription refill database studies have indicated that patients’ adherence to statin medications is generally poor.7–13 Patients who adhere poorly to their regimens are less likely to achieve target levels of low-density lipoprotein14 and are at increased risk of recurrent cardiovascular events.6,15

A search of the literature revealed that previous studies on statin adherence have been conducted using large database records of prescription refills claims. No studies directly asked family practice patients about their adherence to statins and associated factors. In Canada, family practice is an important setting in which to study adherence to statin medications, as most patients receive their cardiovascular preventive care from their family physicians.

Adherence is a complex process, and patients’ decisions on how to manage their medications are likely based on economic, physical, psychological, and social considerations.16 Identifying factors associated with adherence would be of value for formulating strategies to enhance patients’ adherence to statin medications. The objectives of this study were to measure family practice patients’ adherence to statin medications and to identify factors associated with adherence to these medications.

METHODS

Design and setting

The study was approved by the Research Ethics Board of the Capital District Health Authority in Halifax, NS.

Data were obtained from responses to a self-report survey that was mailed to a cross-section of patients from 2 family practices in Halifax. Both practices are academic teaching units; 1 is hospital-based, and the other is community-based. We calculated a sample size of 245 using a 95% confidence interval and a 0.05 specified margin of error. From the medication prescription section of the electronic medical records from these practices,we identified 400 patients aged 40 or older who were prescribed statin medications by their family physicians as new or repeat prescriptions between January 2004 and September 2005. The survey was mailed to the 400 patients using a modified Dillman method.17

Survey

We designed a patient self-report survey. To measure patients’ adherence to statin medications, the survey included the Morisky scale, a 4-item adherence measure18 (Table 118). This scale, originally designed to evaluate medication adherence in hypertensive patients, has been validated and found to be reliable in a variety of medication adherence studies.19–26

View this table:
  • View inline
  • View popup
Table 1

Morisky scale: No—0 points, Yes—1 point; total score of 0—high adherence, 1 to 2—medium adherence, 3 to 4—low adherence.

To identify factors that might be associated with patients’ adherence to statin medications, we developed questions for the survey following a conceptual framework of 38 factors in 7 categories that have previously been thought to affect patients’ adherence to hypertension medications27–29 (Table 2). Hypertension and hyper-lipidemia are asymptomatic, last throughout life, and are managed for prevention of cardiovascular disease. Much research has been conducted in the area of adherence to hypertension medications, and we thought similar factors were likely to affect adherence to statin medications. Face and content validity of the questions were assessed by an experienced survey researcher, a physician, and a pharmacist. The survey was pilot-tested in a community family practice.

View this table:
  • View inline
  • View popup
Table 2

Factors explored in the survey

Analysis

Patients’ adherence to statin medications was measured on the Morisky scale. A high threshold was set for categorizing patients as adherent. Patients who answered “no” to all 4 questions were classified as highly adherent. Patients who answered “yes” to at least 1 question were classified as having medium or low adherence (see scoring in Table 118). This scoring system is consistent with that used in developing the original scale and has been used in other studies to categorize adherence.19–26 As a measure of concurrent criterion validity, we calculated the correlation between patients’ scores on the Morisky scale and their reports of the number of times they had not taken their statin medications in the 30 days before completing the survey.

Univariate logistic regression was used to examine associations between patients’ adherence as rated on the Morisky scale and the 38 patient-reported factors (Table 2). Significant results of univariate analysis were adjusted for age and sex.

Multivariate logistic regression was then carried out using manual backward elimination to determine the most parsimonious model of factors associated with high adherence. The initial model included all factors found to be statistically significant at the level of P = .10 in the univariate analyses. Factors were then sequentially eliminated from the multivariate model until only factors significant at the level of P = .05 remained in the final model. All statistical analysis was done using SAS version 9.1.

RESULTS

Descriptive statistics

The response rate was 82.5%; 330 patients returned the survey. Eighteen patients had discontinued their statin medications, 17 were either taking a non-statin or did not specify what cholesterol-lowering medication they were taking, and 11 had incomplete responses on the Morisky scale. These patients were dropped from the study, leaving an effective sample of 284 patients.

Average age of patients was 65 years (standard deviation ± 10 years), and 57% were men. Sixty-one percent of patients were retired; 41% had college or university education; and 41% had annual income above $50 000. Fifty-seven percent were taking atorvastatin, and 62% had been taking their statin medications for more than 2 years. Nearly all patients (97%) reported that their family physicians managed their cholesterol levels and prescribed their statin medications.

Measurement of adherence

On the Morisky scale, 63.4% of patients reported high adherence, 34.4% reported medium adherence, and 2.2% reported low adherence. There was a high correlation between patients’ scores on the Morisky scale and patients’ reports of the number of times they had not taken their statin medications in the last 30 days (Spearman correlation coefficient r = .70, P < .0001).

Univariate analysis

Few patients reported low adherence on the Morisky scale, so the dependent variable of patient adherence was dichotomized into 2 groups: high adherence versus medium and low adherence. Table 318 shows the significant results (P < .05) of the univariate analyses examining the unadjusted relationships between high scores on the Morisky scale and patient-reported factors.

View this table:
  • View inline
  • View popup
Table 3

Univariate association between high adherence on the Morisky scale18 and patient-reported factors: Only significant results (P < .05) are presented.

Adjusting the significant factors for sex did not affect the strength of their relationship to adherence. When these factors were adjusted for age, only 3 factors remained significant predictors of high adherence: taking 4 to 6 other prescribed medications, having a lifestyle of regular exercise or a healthy diet or both, and a strong belief in the efficacy of statins for reducing the risk of heart attack or stroke.

Multivariate analysis

The initial multivariate model included the following factors found to be statistically significant at the level of P = .10 in the univariate analyses: age, drug insurance coverage, number of other prescribed medications, healthy lifestyle, number of cardiovascular risk factors, current depression or anxiety, secondary versus primary prevention, belief that statins reduce risk of heart attack or stroke, and frequency of visits to family doctors. In the final most parsimonious model, being older than 65, taking 4 to 6 other prescribed medications, and having a lifestyle of regular exercise or a healthy diet or both remained independent significant predictors of high adherence as measured by the Morisky scale (Table 418).

View this table:
  • View inline
  • View popup
Table 4

Final multivariate model of association between high adherence on the Morisky scale18 and patient-reported factors

DISCUSSION

In this study of patients prescribed statin medications by their family physicians, 63% reported a high level of adherence. Other studies of statin adherence are based on large database analyses of patient prescription refill claims. Rates of adherence to statins in these studies vary depending on the definition of adherence used. Four large database studies using a definition of adherence of at least 80% of days covered by a statin prescription found that 40% to 60% of patients were adherent during the first 1 to 2 years of new prescriptions.8–10,30

There could be several reasons for the relatively high level of adherence reported by patients in our study. First, 2 previous American studies had reported that lower out-of-pocket expense increased patient adherence to statin therapy.11,14 Almost 90% of our patients had drug insurance coverage, so cost of medication was not a barrier. Second, studies suggest that patients’ adherence to statins declines substantially in the first 1 to 2 years of treatment but then stabilizes over time.8,10,12,30 In our study, more than 60% of patients had been taking their statins for more than 2 years.

Several factors were found to be strongly associated with high adherence to statins in our study. Patients older than 65 years were more than 3 times as likely to report high adherence as those between the ages of 40 and 54. In some database studies, older age was also found to be associated with better adherence. Results from other studies, however, indicate either no association with older age or that adherence actually decreased with increasing age.7–11,13

Patients who were taking 4 to 6 other medications were more than twice as likely to report high adherence as those taking fewer than 4 or more than 6 other medications. Two previous database studies of prescription claims found that patients who claimed a greater number of concurrent medications were more adherent to their statins.9,31 Two other database studies found the opposite effect.7,13 Given the results of our study and these other studies, it appears that there might be a minimum number of concurrent medications that optimizes patient adherence; in our study, this was 4 medications. Adherence is maintained only up to a threshold number of concurrent medications; in our study, 6. Then adherence begins to decline with the increasing complexity of the medication regimen.

Patients in our study who reported that they maintained a lifestyle of regular exercise or a healthy diet or both were more than 3 times as likely to report high adherence. Thus, if patients are encouraged to maintain a healthy lifestyle they might be more adherent to their statin medications. Clinical practice guidelines for treatment of dyslipidemia established by the Canadian Cardiovascular Society also promote regular exercise and healthy eating as the cornerstones of heart disease prevention.32

It has been recognized that patients’ beliefs about prescribed medications can be a predictor of adherence.16,26 In our study, univariate analysis indicated that patients who strongly believed that taking statins reduced their risk of having heart attacks or strokes were more than twice as likely to report high adherence. Similarly, in a French study that surveyed 193 hyperlipidemic patients coming to a specialty endocrine clinic, patients reported better adherence to statin medications if they believed these medications lowered their risk of future cardiovascular events.33

Limitations

We acknowledge several limitations to our study. First, participants were all drawn from 2 academic family practices that might not be representative of all family practice settings. Second, patients could be overestimating their adherence in their self-reports in order to give socially acceptable responses. No method of measuring adherence is considered a criterion standard, however, and all methods have limitations.34 Indirect methods, such as database analysis, only estimate actual patient behaviour, and more direct testing, for example of serum drug levels, is complicated and expensive. In our study, we used a well-validated scale and set a high threshold for classifying patients as adherent. In order to diminish reporting bias, patients were asked to return the survey anonymously and were guaranteed that no feedback would be given to their health care providers. A third limitation of our study was that we explored a large number of factors and our sample size might not have been large enough to detect significant associations between adherence and some of the factors.

Conclusion

More than 63% of patients prescribed statins by their family physicians reported high adherence to these medications. Strategies to improve adherence would best be directed at patients who are younger or taking fewer than 4 or more than 6 other prescribed medications. Patients should be encouraged to maintain a lifestyle of regular exercise and a healthy diet as this was associated with better adherence. Future research should be directed at formulating strategies to enhance patients’ adherence to statin medications; such strategies might best be implemented in family practice settings.

Acknowledgment

We thank Dr Cindy Marshall for her assistance conducting the pilot project. We also wish to thank members of the Primary Care Research Unit in the Department of Family Medicine at Dalhousie University for their support.

Notes

EDITOR’S KEY POINTS

  • Adherence to statin medications is thought to be generally poor, but most studies of adherence to statins are based on analyses of large databases of patient prescription refill claims.

  • In this study of patients prescribed statin medications by their family physicians, 63% reported a high level of adherence.

  • Several factors were found to be associated with high levels of adherence: being older than 65 years, taking 4 to 6 other medications, and having a lifestyle that includes regular exercise or a healthy diet.

POINTS DE REPÈRE DU RÉDACTEUR

  • On croit généralement que les patients sont peu fidèles à la prise de statines, mais la plupart des études sur ce sujet sont basées sur l’analyse de grandes bases de données portant sur les demandes de renouvellement de prescriptions par les patients.

  • Dans cette étude, 63% des patients qui avaient reçu une prescription de statines de leur médecin de famille ont déclaré être très fidèles à ce traitement.

  • On a trouvé que plusieurs facteurs sont associés à un taux élevé d’observance: le fait d’être plus âgé, de prendre de 4 à 6 autres médicaments et d’avoir un mode de vie comprenant exercice régulier et alimentation saine.

Footnotes

  • Contributors

    Dr Natarajan contributed to initial development of the research question and study design, created the survey and oversaw its administration, contributed to analysis of the data, and wrote the paper. Dr Putnam contributed to development of the research question, the study design, and the survey, and edited the paper for intellectual content. Ms Yip conducted the data analysis and contributed to writing the paper. Ms Frail contributed to the research question, the study design, and the survey, and edited the paper for intellectual content.

  • Competing interests

    None declared

  • This article has been peer reviewed.

  • Copyright© the College of Family Physicians of Canada

References

  1. ↵
    Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
    OpenUrlCrossRefPubMed
    1. Sacks FM,
    2. Pfeffer MA,
    3. Moye LA,
    4. Rouleau JL,
    5. Rutherford JD,
    6. Cole TG,
    7. et al
    . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med 1996;335:1001-9.
    OpenUrlCrossRefPubMed
  2. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl J Med 1998;339:1349-57.
    OpenUrlCrossRefPubMed
    1. Downs JR,
    2. Clearfield M,
    3. Weis S,
    4. Whitney E,
    5. Shapiro DR,
    6. Beere PA,
    7. et al
    . Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279(20):1615-22.
    OpenUrlCrossRefPubMed
  3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360(9236):7-22.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Shepherd J,
    2. Cobbe SM,
    3. Ford I,
    4. Isles CG,
    5. Lorimer AR,
    6. MacFarlane PW,
    7. et al
    . Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Jackevicius CA,
    2. Mamdani M,
    3. Tu JV
    . Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288(4):462-7.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Blackburn DF,
    2. Dobson RT,
    3. Blackburn JL,
    4. Wilson TW,
    5. Stang MR,
    6. Semchuk WM
    . Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol 2005;21(6):485-8.
    OpenUrlPubMed
  7. ↵
    1. Benner JS,
    2. Glynn RJ,
    3. Mogun H,
    4. Neumann PJ,
    5. Weinstein MC,
    6. Avorn J
    . Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288(4):455-61.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Caspard H,
    2. Chan AK,
    3. Walker AM
    . Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia. Clin Ther 2005;27(10):1639-46.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Ellis JJ,
    2. Erickson SR,
    3. Stevenson JG,
    4. Bernstein SJ,
    5. Stiles RA,
    6. Fendrick AM
    . Suboptimal statin adherence and discontinuation in primary and secondary prevention populations: should we target patients with the most to gain? J Gen Intern Med 2004;19:638-45.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Perreault S,
    2. Blais L,
    3. Dragomir A,
    4. Bouchard M-H,
    5. Lalonde L,
    6. Laurier C,
    7. et al
    . Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol 2005;61:667-74.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Avorn J,
    2. Monette J,
    3. Lacour A,
    4. Bohn RL,
    5. Monane M,
    6. Mogun H,
    7. et al
    . Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998;279(18):1458-62.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Schultz JS,
    2. O’Donnell JC,
    3. McDonough KL,
    4. Sasane R,
    5. Meyer J
    . Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care 2005;11:306-12.
    OpenUrlPubMed
  13. ↵
    1. Wei L,
    2. Wang J,
    3. Thompson P,
    4. Wong S,
    5. Struthers AD,
    6. MacDonald TM
    . Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002;88:229-33.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Vermeire E,
    2. Hearnshaw H,
    3. Van Royen P,
    4. Denekens J
    . Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001;26:331-42.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Salant P,
    2. Dillman DA
    . How to conduct your own survey. New York, NY: John Wiley & Sons; 1994.
  16. ↵
    1. Morisky DE,
    2. Green LW,
    3. Levine DM
    . Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24(1):67-74.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Sung JC,
    2. Nichol MB,
    3. Venturini F,
    4. Bailey KL,
    5. McCombs JS,
    6. Cody M
    . Factors affecting patient compliance with antihyperlipidemic medications in an HMO population. Am J Manag Care 1998;4:1421-30.
    OpenUrlPubMed
    1. Krapek K,
    2. King K,
    3. Warren SS,
    4. George KG,
    5. Caputo DA,
    6. Mihelich K,
    7. et al
    . Medication adherence and associated hemoglobin A1C in type 2 diabetes. Ann Pharmacother 2004;38(9):1357-62.
    OpenUrlCrossRefPubMed
    1. Venturini F,
    2. Nichol MB,
    3. Sung JCY,
    4. Bailey KL,
    5. Cody M,
    6. McCombs JS
    . Compliance with sulfonylureas in a health maintenance organization: a pharmacy record-based study. Ann Pharmacother 1999;33:281-8.
    OpenUrlAbstract/FREE Full Text
    1. George CF,
    2. Peveler RC,
    3. Heiliger S,
    4. Thompson C
    . Compliance with tricyclic antidepressants: the value of four different methods of assessment. Br J Clin Pharmacol 2000;50:166-71.
    OpenUrlCrossRefPubMed
    1. Turbí C,
    2. Herrero-Beaumont G,
    3. Acebes JC,
    4. Torrijos A,
    5. Graña J,
    6. Miguélez R,
    7. et al
    . Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 2004;26(2):245-56.
    OpenUrlCrossRefPubMed
    1. Patel RP,
    2. Taylor SD
    . Factors affecting medication adherence in hypertensive patients. Ann Pharmacother 2002;36:40-5.
    OpenUrlAbstract/FREE Full Text
    1. Gascón JJ,
    2. Sánchez-Ortuño M,
    3. Llor B,
    4. Skidmore D,
    5. Saturno PJ
    . Why hypertensive patients do not comply with the treatment: results from a qualitative study. Fam Pract 2004;21:125-30.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Horne R,
    2. Weinman J
    . Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999;47(6):555-67.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Krousel-Wood M,
    2. Thomas S,
    3. Muntner P,
    4. Morisky D
    . Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 2004;19:357-62.
    OpenUrlCrossRefPubMed
  20. World Health Organization. Hypertension in adherence to long-term therapies: evidence for action. Geneva, Switz: World Health Organization; 2003. p. 107-14.
  21. ↵
    1. Grégoire J-P,
    2. Moisan J,
    3. Guibert R,
    4. Ciampi A,
    5. Milot A,
    6. Gaudet M,
    7. et al
    . Determinants of discontinuation of new courses of antihypertensive medications. J Clin Epidemiol 2002;55:728-35.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Lachaine J,
    2. Rinfret S,
    3. Merikle EP,
    4. Tarride J-E
    . Persistence and adherence to cholesterol lowering agents: evidence from Régie de l’Assurance Maladie du Québec data. Am Heart J 2006;152(1):164-9.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Grant RW,
    2. O’Leary KM,
    3. Weilburg JB,
    4. Singer DE,
    5. Meigs JB
    . Impact of concurrent medication use on statin adherence and refill persistence. Arch Intern Med 2004;164:2343-8.
    OpenUrlCrossRefPubMed
  24. ↵
    1. McPherson R,
    2. Frohlich J,
    3. Fodor G,
    4. Genest J
    . Canadian Cardiovascular Society position statement—recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22(11):913-27.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Kiortsis DN,
    2. Giral P,
    3. Bruckert E,
    4. Turpin G
    . Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients. J Clin Pharm Ther 2000;25:445-51.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Farmer KC
    . Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 1999;21(6):1074-90.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 53 (12)
Canadian Family Physician
Vol. 53, Issue 12
1 Dec 2007
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Family practice patients’ adherence to statin medications
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Family practice patients’ adherence to statin medications
Nandini Natarajan, R. Wayne Putnam, Alexandra M. Yip, Dawn Frail
Canadian Family Physician Dec 2007, 53 (12) 2144-2145;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Family practice patients’ adherence to statin medications
Nandini Natarajan, R. Wayne Putnam, Alexandra M. Yip, Dawn Frail
Canadian Family Physician Dec 2007, 53 (12) 2144-2145;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgment
    • Notes
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Potential contribution of lifestyle and socioeconomic factors to healthy user bias in antihypertensives and lipid-lowering drugs
  • Lifestyle factors as predictors of nonadherence to statin therapy among patients with and without cardiovascular comorbidities
  • Google Scholar

More in this TOC Section

  • First-trimester surgical abortion practice in Canada in 2012
  • Abdominal aortic aneurysm screening in an academic family practice
  • Focused practice in family medicine
Show more Research

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2023 by The College of Family Physicians of Canada

Powered by HighWire